DBV Applied sciences (NASDAQ:DBVT) Now Coated by StockNews.com

DBV Technologies logoEquities analysis analysts at StockNews.com initiated protection on shares of DBV Applied sciences (NASDAQ:DBVT – Get Score) in a analysis observe issued to buyers on Friday. The brokerage units a “promote” ranking on the inventory.

Individually, Kepler Capital Markets upgraded shares of DBV Applied sciences from a “maintain” ranking to a “purchase” ranking and set a €6.00 ​​($6.12) goal worth on the inventory in a analysis report on Thursday, August 4th. One equities analysis analyst has rated the inventory with a promote ranking, three have given a maintain ranking and three have given a purchase ranking to the inventory. Based on MarketBeat.com, the inventory presently has a mean ranking of “Maintain” and a consensus goal worth of $5.63.

DBV Applied sciences Buying and selling Down 0.6%

Shares of NASDAQ DBVT opened at $1.59 on Friday. The inventory’s 50-day transferring common is $2.05 and its 200 day transferring common is $1.97. The inventory has a market cap of $299.00 million, a price-to-earnings ratio of -2.34 and a beta of 1.49. DBV Applied sciences has a 1-year low of $1.15 and a 1-year excessive of $5.60.

Need Extra Nice Investing Concepts?

DBV Applied sciences (NASDAQ:DBVT – Get Score) final issued its quarterly earnings outcomes on Monday, August 1st. The corporate reported ($0.18) EPS for the quarter, lacking analysts’ consensus estimates of ($0.17) by ($0.01). The enterprise had income of $1.53 million for the quarter, in comparison with the consensus estimate of $2.57 million. DBV Applied sciences had a destructive web margin of 929.78% and a destructive return on fairness of 57.09%. On common, analysts forecast that DBV Applied sciences will publish -0.68 EPS for the present fiscal yr.

Institutional Inflows and Outflows

Institutional buyers and hedge funds have just lately made modifications to their positions within the firm. Black Rock Inc. raised its holdings in DBV Applied sciences by 16.5% throughout the 1st quarter. Black Rock Inc. now owns 687,341 shares of the corporate’s inventory valued at $1,093,000 after shopping for an extra 97,412 shares over the last quarter. ExodusPoint Capital Administration LP bought a brand new place in shares of DBV Applied sciences within the second quarter valued at about $352,000. BNP Paribas Arbitrage SA purchased a brand new place in shares of DBV Applied sciences throughout the second quarter valued at about $49,000. Lastly, Advisory Companies Community LLC bought a brand new stake in shares of DBV Applied sciences throughout the second quarter value about $26,000. Institutional buyers personal 27.55% of the corporate’s inventory.

DBV Applied sciences Firm Profile

(Get Score)

DBV Applied sciences SA, a clinical-stage biopharmaceutical firm, engages within the analysis and growth of epicutaneous immunotherapy merchandise. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has accomplished Part III scientific trial for the therapy of peanut allergy symptoms in 4 to 11 years of age kids, adolescents, and adults.

Learn Extra

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Obtain Information & Rankings for DBV Applied sciences Every day – Enter your electronic mail handle beneath to obtain a concise day by day abstract of the newest information and analysts’ scores for DBV Applied sciences and associated corporations with MarketBeat.com’s FREE day by day electronic mail publication.